Female Urology

The study considered 4 dimensions of the workplace: equal access, work-life balance, freedom from gender bias, and supportive leadership.

The patient-focused book entitled Pelvic Floor Health: Your Guide to Pregnancy and Postpartum Care is now available in paperback and e-book.

“We need to be focusing our efforts on early exposure to the field for women and underrepresented groups,” says Bridget Lang Findlay, MD.

Dr. Van Kuiken discusses 2022 milestones in FPMRS and looks ahead to what might be on the horizon for the field in the coming year.

“The bottom line is that [gender parity] starts with sponsorship and bringing women to the table in academic leadership positions so that our voices can be heard,” says Bridget Lang Findlay, MD.

The American Urogynecologic Society's Pelvic Floor Disorders (PFD) Week 2023 is the year’s largest venue for those in the field of urogynecology and Female Pelvic Medicine and Reconstructive Surgery to come together for education and networking.

There are several elements of ERAS with strong evidence of benefit in urogynecological surgery.

The phase 3 EAGLE-2 and EAGLE-3 studies looked at outcomes for gepotidacin, an investigational agent for the treatment of uncomplicated urinary tract infection.

Register for AUGS Clinical Meeting 2022, Beyond Urogynecology: Pearls for Best Practice.

The FDA decided a New Drug Application lacked sufficient data to approve tebipenem pivoxil hydrobromide (tebipenem HBr) for the treatment of patients with complicated urinary tract infection.

In this interview, coauthors Connie Huang, MD, and Jason M. Kim, MD, discuss the findings of their recent study, "Urinary Tract Infection on social media: Examining YouTube content as a source of patient educational information."

“We know that, in general, cystectomy in women can disrupt pelvic floor support and innervation, as well as hormonal and sexual function, but there are no good prospective data to help us fully understand pelvic floor complications following the procedure,” said Jacqueline Zillioux, MD.

The FDA is evaluating a new drug application for oral tebipenem pivoxil hydrobromide for the treatment of patients with complicated urinary tract infection, including acute pyelonephritis.

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

A study presented at the 2022 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Winter Meeting evaluated the safety and efficacy of percutaneous tibial nerve stimulation (PTNS) in patients who suffer from female sexual dysfunction.

Jerry G. Blaivas, MD, FACS, debunks some of the common stigmas associated with mesh slings.

A recent study presented at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference investigated the quality of information regarding urinary tract infections on the social media platform Reddit.

“To me, the overwhelming thing is understanding that treatments are, by and large, effective,” says Jerry G. Blaivas, MD, FACS.

"Many people do not examine patients who come in with urinary tract infections or overactive bladder symptoms, and it’s a mistake,” says Rachel S. Rubin, MD.

As an advocate for patients, Svetlana Avulova, MD, stresses the importance of this population of women with bladder cancer and how their desire to preserve sexual function through organ-sparing treatment should be recognized and validated.

“I think discussing it and talking about the different techniques out there [is important],” says Svetlana Avulova, MD.

“I think it's important for people to recognize this revolution that's going on, to see that we're going from what fell to why it fell,” says John O. L. DeLancey, MD.

"It depends on how you're paid and the structure of the compensation model," says Jennifer Miles-Thomas, MD, FPMRS.

Jennifer Miles-Thomas, MD, FPMRS, explains why urology practices need to have female urologists and approaches for recruiting them.

"We're moving from an era where it was all based on judgment, and experience, to an era where treatments will be based on firm evidence of the structural failures present in each patient," says John O. L. DeLancey, MD.